Global Endometriosis Drugs Market to Reach $3.3 Billion by 2030
The global market for Endometriosis Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$3.3 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2022-2030. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analgesics segment is readjusted to a revised 2% CAGR for the next 8-year period.The U.S. Market is Estimated at $777.8 Million, While China is Forecast to Grow at 2.4% CAGR
The Endometriosis Drugs market in the U.S. is estimated at US$777.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.Select Competitors (Total 38 Featured) -
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Debiopharm Group
- Evotec AG
- Kissei Pharmaceutical Co. Ltd.
- Neurocrine Biosciences Inc.
- ObsEva SA
- Pfizer Inc.
- Repros Therapeutics Inc.
- Takeda Pharmaceutical Company Limited
- ValiRx plc
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Debiopharm Group
- Evotec AG
- Kissei Pharmaceutical Co. Ltd.
- Neurocrine Biosciences Inc.
- ObsEva SA
- Pfizer Inc.
- Repros Therapeutics Inc.
- Takeda Pharmaceutical Company Limited
- ValiRx plc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 191 |
Published | April 2024 |
Forecast Period | 2020 - 2027 |
Estimated Market Value ( USD | $ 2.4 Billion |
Forecasted Market Value ( USD | $ 2.9 Billion |
Compound Annual Growth Rate | 2.7% |
Regions Covered | Global |